Renal outcomes in myeloma associated acute kidney injury; a single centre experience

IF 0.2 Q4 UROLOGY & NEPHROLOGY
Shivendra Singh, H. Sreenidhi
{"title":"Renal outcomes in myeloma associated acute kidney injury; a single centre experience","authors":"Shivendra Singh, H. Sreenidhi","doi":"10.34172/jrip.2022.32020","DOIUrl":null,"url":null,"abstract":"Introduction: At initial diagnosis of multiple myeloma (MM) 30% to 40% of patients has renal impairment and acute kidney injury (AKI) being most common renal presentation. Poor renal outcome is associated with poor overall survival of patients. Objectives: The present study was conducted to determine renal outcome in patients with newly diagnosed MM presenting with AKI. Patients and Methods: A prospective observational study was carried out from March 2016 to March 2021. We included newly diagnosed myeloma patients presenting with AKI. Diagnosis and staging of AKI was conducted by kidney disease improving global outcomes (KDIGO) guidelines. Diagnosis of MM was performed by International Myeloma Working Group (IMWG) criteria. Complete renal response was defined as estimated glomerular filtration rate (eGFR) of ≥60 mL/min. Statistical analysis was done using SPSS Statistics software version 28. Results: Total number of patients were 48 male, female was 32.16, median age was 69 years. With a median follow-up of 9 weeks 30 patients (62.5%) had complete renal response, 10 patients (20.8%) expired and 8 patients (16.6%) were dialysis dependent. On comparing patients with and without complete renal response, significant variables were serum creatinine (P<0.001), serum calcium (P<0.001), oliguria at presentation (P<0.001), RRT requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma(P<0.001). On Kaplan Meier analysis oliguria at presentation (P<0.001), renal replacement therapy (RRT) requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma (P<0.001) were significantly associated with poor renal outcomes. Conclusion: In patients with newly diagnosed MM presenting with AKI renal recovery is 62.5%. Factors associated with poor renal recovery are higher serum creatinine, oliguria, RRT requirement, AKI stage Ⅲ and light chain myeloma.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2022.32020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: At initial diagnosis of multiple myeloma (MM) 30% to 40% of patients has renal impairment and acute kidney injury (AKI) being most common renal presentation. Poor renal outcome is associated with poor overall survival of patients. Objectives: The present study was conducted to determine renal outcome in patients with newly diagnosed MM presenting with AKI. Patients and Methods: A prospective observational study was carried out from March 2016 to March 2021. We included newly diagnosed myeloma patients presenting with AKI. Diagnosis and staging of AKI was conducted by kidney disease improving global outcomes (KDIGO) guidelines. Diagnosis of MM was performed by International Myeloma Working Group (IMWG) criteria. Complete renal response was defined as estimated glomerular filtration rate (eGFR) of ≥60 mL/min. Statistical analysis was done using SPSS Statistics software version 28. Results: Total number of patients were 48 male, female was 32.16, median age was 69 years. With a median follow-up of 9 weeks 30 patients (62.5%) had complete renal response, 10 patients (20.8%) expired and 8 patients (16.6%) were dialysis dependent. On comparing patients with and without complete renal response, significant variables were serum creatinine (P<0.001), serum calcium (P<0.001), oliguria at presentation (P<0.001), RRT requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma(P<0.001). On Kaplan Meier analysis oliguria at presentation (P<0.001), renal replacement therapy (RRT) requirement (P<0.001), AKI stage Ⅲ (P<0.001) and light chain myeloma (P<0.001) were significantly associated with poor renal outcomes. Conclusion: In patients with newly diagnosed MM presenting with AKI renal recovery is 62.5%. Factors associated with poor renal recovery are higher serum creatinine, oliguria, RRT requirement, AKI stage Ⅲ and light chain myeloma.
骨髓瘤相关急性肾损伤的肾脏预后单一中心体验
简介:在多发性骨髓瘤(MM)的初始诊断中,30%至40%的患者有肾脏损害,急性肾损伤(AKI)是最常见的肾脏表现。肾脏预后差与患者的总生存率差有关。目的:本研究旨在确定新诊断MM合并AKI患者的肾脏预后。患者和方法:一项前瞻性观察性研究于2016年3月至2021年3月进行。我们纳入了以AKI为表现的新诊断的骨髓瘤患者。AKI的诊断和分期由肾脏疾病改善全球预后(KDIGO)指南进行。MM的诊断采用国际骨髓瘤工作组(IMWG)标准。完全肾反应定义为肾小球滤过率(eGFR)≥60 mL/min。采用SPSS统计软件28版进行统计分析。结果:患者中男性48例,女性32.16例,中位年龄69岁。中位随访时间为9周,30例患者(62.5%)肾脏完全缓解,10例患者(20.8%)过期,8例患者(16.6%)依赖透析。在比较有和没有完全肾反应的患者时,显著变量是血清肌酐(P<0.001)、血清钙(P<0.001)、首发时少尿(P<0.001)、RRT需求(P<0.001)、AKI分期Ⅲ(P<0.001)和轻链骨髓瘤(P<0.001)。Kaplan Meier分析显示,就诊时尿少(P<0.001)、肾脏替代治疗(RRT)需求(P<0.001)、AKI分期Ⅲ(P<0.001)和轻链骨髓瘤(P<0.001)与不良肾脏预后显著相关。结论:在新诊断的MM患者中,肾恢复率为62.5%。与肾功能恢复不良相关的因素有血清肌酐升高、少尿、RRT需求、AKI分期Ⅲ和轻链骨髓瘤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Renal Injury Prevention
Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
36
期刊介绍: The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信